<DOC>
	<DOCNO>NCT02310581</DOCNO>
	<brief_summary>This phase 3 , multicenter , randomize , double-blind , multiple-dose , parallel-group , placebo-controlled study evaluate safety efficacy 3 dosing regimen Buprenorphine Sublingual Spray and/or match placebo subject moderate severe postoperative pain bunionectomy . The study comprise 4 period : Screening Period , Surgical Period , Treatment Period , Follow-up Period . Subjects admit study site morning schedule surgery , remain study site postoperative Day 3 ( total 3 night study site ) , return Follow-up Visit 5 9 day surgery .</brief_summary>
	<brief_title>Buprenorphine Sublingual Spray Treatment Moderate Severe Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Meets protocolspecified criterion qualification contraception Is able speak understand language study conduct , able understand procedure study requirement voluntarily sign date informed consent form approve Institutional Review Board conduct study procedure Is willing able comply study requirement ( include diet , alcohol , smoke restriction ) , complete pain evaluation , remain study site three day , return follow 7 9 day surgery . History current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Signs , symptoms history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bunionectomy</keyword>
</DOC>